The company, which is developing a treatment or psoriasis and arthritis, raised part of the $10m round from clinical testing companies and has now raised $46m since it was founded.
US-based biotechnology company Kineta has raised the first part of a $10m funding round for a drug investment subsidiary from MPI Research and other clinical testing companies, CEO Chuck Mangess told Xconomy on Thursday.
The companies in question will also work with Kineta on its drug candidates, the first of which will be for a candidate meant to treat psoriasis and psoriatic arthritis sufferers.
Kineta raised funds in May 2013 from Hydra, an organisation made up of ex-oil traders, and…
